569 related articles for article (PubMed ID: 32983123)
1. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
3. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
4. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
6. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
7. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Castelli V; Cimini A; Ferri C
Front Immunol; 2020; 11():2132. PubMed ID: 32983172
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
10. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
11. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
12. IL-6: Relevance for immunopathology of SARS-CoV-2.
Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
Smetana K; Rosel D; BrÁbek J
In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847
[TBL] [Abstract][Full Text] [Related]
14. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A
Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824
[No Abstract] [Full Text] [Related]
15. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
[TBL] [Abstract][Full Text] [Related]
16. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
León López R; Fernández SC; Limia Pérez L; Romero Palacios A; Fernández-Roldán MC; Aguilar Alonso E; Pérez Camacho I; Rodriguez-Baño J; Merchante N; Olalla J; Esteban-Moreno MÁ; Santos M; Luque-Pineda A; Torre-Cisneros J
BMJ Open; 2020 Nov; 10(11):e039951. PubMed ID: 33191263
[TBL] [Abstract][Full Text] [Related]
19. Why tocilizumab could be an effective treatment for severe COVID-19?
Fu B; Xu X; Wei H
J Transl Med; 2020 Apr; 18(1):164. PubMed ID: 32290839
[TBL] [Abstract][Full Text] [Related]
20. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
